fb tracking

Testimony Before the FDA’s Medical Imaging Drugs Advisory Committee Regarding the Safety of Linear Gadolinium-based Contrast Agents

View as PDF.

In testimony before a meeting of the Food and Drug Administration’s (FDA’s) Medical Imaging Drugs Advisory Committee, Public Citizen urged the committee to recommend that the FDA adopt the approach of the European Medicines Agency and ban and restrict linear gadolinium-based contrast agents used in MRIs because they can remain deposited in the brain for months or even years and, with certain exceptions, offer no unique benefits over potentially safer, more widely used macrocyclic gadolinium-based products.